Clinical efficacy of TroVax in the treatment of progressive castration-resistant prostate cancer

Clinical Medicine Insights: Oncology

Volumn 6, Issue , 2012, Pages 63-73

  Amato, Robert J ^a   Stepankiw, Mika ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer vaccines; MVA 5T4; Prostate cancer; TroVax

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; PROSTATE SPECIFIC ANTIGEN;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; BONE DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENICITY; CASTRATION RESISTANT PROSTATE CANCER; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEVER; HEPATITIS C; HUMAN; IMMUNE RESPONSE; INJECTION SITE IRRITATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; REVIEW; VIRAL GENE DELIVERY SYSTEM;

EID: 84856999917     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S7654     Document Type: Review

References (39)

1. National Cancer Institute. A Snapshot of Prostate Cancer. September 2010. http://www.cancer.gov/PublishedContent/Files/aboutnci/servingpeople/snapshots/2010_prostate_508.pdf.
2. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-22.
3. Amato RJ. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy. Expert Opin Biol Ther. 2007;7(9):1463-9.
4. Harrop R, John J, Carrol MW. Recombinant viral vectors: cancer vaccines. Adv Drug Delivery Rev. 2006;588:931-47.
5. Crawford ED, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321:419-24.
6. Group PCTC. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5711 patients. Lancet. 1995;346:265-9.
7. Dresden S, Olson K, Pienta K. Gleason score as a prognostic marker of survival in men with advanced prostate cancer. Proc ASCO. 2001:2422(a).
8. Small E, Vogelzang N. Second-line hormonal therapy for advanced prostate cancer: a shiftring paradigm. J Clin Oncol. 1997;15(1):382-8.
9. Scher H, Kelly W, et al. Clinical trials in relapsed prostate cancer: defining the target. J Natl Cancer Inst. 1996;88(22):1623-34.
10. Starzynska T, Marsh P, Schofield P, et al. Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer. 1994;69: 899-902.
11. Griffiths RW, Gilham DR, Dangoor A, et al. Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer. 2005;93(6):670-7.
12. Barrow KM, Ward CM, Rutter J, Ali S, Stern PL. Embryonic expression of murine 5T4 oncofetal antigen is associated with morphogenetic events at implantation and in developing epithelia. Devel Dynamics. 2005;233(4): 1535-45.
13. National Cancer Institute. A snapshot of prostate cancer. September 2010. http://www.cancer.gov/PublishedContent/Files/aboutnci/servingpeople/snapshots/2010_prostate_508.pdf.
14. Surveillane Epidemiology and End Results. SEER Stat Fact Sheets Prostate. 2010. http://seer.cancer.gov/statfacts/html/prost.html.
15. Waeckerle-Men Y, Allmen EU, Fopp M, et al. Dendritic cell-based multiepitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother. 2009;55:1524-33.
16. Oudard S. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol. Apr 2011;7(4): 497-506.
17. Michaelson MD, Oudard S, Ou Y, et al. Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). 2011 ASCO Annual Meeting. J Clin Oncol. 2011; 29:(suppl; abstr 4515).
18. Thomas-Kaskel AK, Zeiser R, Jochim R, et al. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall performance. Int J Cancer. 2006;199:2428-34.
19. Hochstein-Mintzel et al. Virulence and immunogenicity of a modified vaccinia virus (Strain MVA). Z Immunitatsforsch ExpKlin Immunol. 1972;144(2):104-56.
20. Mayr et al. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behaviour in organisms with a debilitated defence mechanism. Zentralbi Bakteriol. 1978;167(5):375-90.
21. Mahnel, Mayr. Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA. Berl Munch Tierarztl Wochenschr. 1994;107(8):253-6.
22. Hole N, Stern PL. A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer. 1988;57:237-46.
23. Southall P, Boxer G, Bagshaw K, et al. Immunological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer. 1990;61:89-95.
24. Sutter G, Moss B. Non-replicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci. 1992;89:10847-51.
25. Owverjik WW, et al. Gp100/pmel 17 is a murine tumour rejection antigen: induction of "self"-reactive tumouricidal T cells using high-affinity, altered peptide ligand. J Exp Med. 1998:277-86
26. Owverjik WW. et al. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces anautoimmune vitiligo and tumour cell destruction in mine: requirement for CD4(+)T lymphocytes. Proc Natl Acad Sci USA. 1999;96:2982-7.
27. McAneny D, et al. Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann Surg Oncol. 1996;3(5):495-500.
28. Tsang TY, et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst. 1995;87(13):982-90.
29. Mayr et al. Passage history, properties and applicability of the attenuated vaccinia virus strain MVA Infection. 1975;3:6-14.
30. Meyr et al. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. Gen Virol. 1991;72(5):1031-8.
31. Harrop R, Connolly NB, Redchenko I, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a Phase I/II Trial. Clin Cancer Res. 2006;12(11):3416-24.
32. Amato RJ, Drury N, Naylor S, et al. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): A phase 2 trial. J Immunother. 2008;31(6):577-85.
33. Amato RJ, Hawkins RE, Kaufman HL, et al. Vaccination of metastatic renal cancer patients with MVA-5T4: A randomized, double-blind, placebocontrolled phase III study. Cancer Res. 2010;doi:10.1158/1078.
34. Oudard S, Banu E, Beuzeboc P, et al. Multicenter randomized phase II study of two schedules of Docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone inpatients with metastatic hormone-refractory prostate cancer. J Clin Onc. 2005;23(15)3343-33551.
35. Chan OT, Yang LX. The immunological effects of taxanes. Cancer Immunol Immunother. 2000;49:181-5.
36. Mason K, Stabb A, Hunter N, et al. Enhancement of tumor radioresponse by Docetaxel: involvement of immune system. Int J Oncol. 2001;18:599-606.
37. Arlen PM, Gulley JL, Parker C, et al. A randomized phase II study of concurrent Docetaxel plus vaccine versus vaccine alone in metastatic androgenindependent prostate cancer. Clin Cancer Res. 2006;12(4):1260-9.
38. Schlom J, Arlen P, Gulley J. Cancer Vaccines: Moving Beyond Current Paradigms. Clin Can Res. 2007;13(13):3776-82.
39. Oxford BioMedica. A randomized phase II study to assess the activity of TroVax (MVA-5T4) plus docetaxel versus docetaxel alone in subjects with progressive hormone refractory prostate cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2011- [citedOctober 31, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01194960?term=trovax&rank=5 NLM Identifier: NCT01194960.